Danirixin
- Generic Name
- Danirixin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C19H21ClFN3O4S
- CAS Number
- 954126-98-8
- Unique Ingredient Identifier
- R318PGH5VP
- Background
Danirixin has been used in trials studying the treatment and basic science of Virus Diseases, Nutritional Status, Pulmonary Disease, Chronic Obstructive, and Infections, Respiratory Syncytial Virus.
- Associated Conditions
- -
- Associated Therapies
- -
GSK1325756 Relative Bioavailability Study in Healthy Elderly Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2021-05-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 40
- Registration Number
- NCT03457727
- Locations
- 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States
Randomized Study Evaluating the Effect of Danirixin on Neutrophil Extracellular Traps (NETs) in Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2017-08-16
- Last Posted Date
- 2021-03-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 19
- Registration Number
- NCT03250689
- Locations
- 🇬🇧
GSK Investigational Site, Dundee, United Kingdom
Danirixin Dose Ranging Study in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-01-27
- Last Posted Date
- 2020-10-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 614
- Registration Number
- NCT03034967
- Locations
- 🇪🇸
GSK Investigational Site, Zaragoza, Spain
Evaluation of Danirixin (GSK1325756) Inhibition of CD11b Cell Surface Expression
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-07-28
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 40
- Registration Number
- NCT02201303
- Locations
- 🇺🇸
GSK Investigational Site, Syracuse, New York, United States
Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-05-05
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 102
- Registration Number
- NCT02130193
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath